
Quarterly report 2025-Q3
added 11-17-2025
Zynex Revenue 2011-2026 | ZYXI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 192 M | 184 M | 158 M | 130 M | 80.1 M | 45.5 M | 31.9 M | 23.4 M | 13.3 M | 11.6 M | 11.1 M | 21.7 M | 39.7 M | 34.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 192 M | 11.1 M | 69.8 M |
Quarterly Revenue Zynex
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.4 M | 22.3 M | 26.6 M | - | 50 M | 49.9 M | 46.5 M | - | 49.9 M | 45 M | 42.2 M | - | 41.5 M | 36.8 M | 31.1 M | 40.4 M | 34.8 M | 31 M | 24.1 M | 25.6 M | 20 M | 19.3 M | 15.2 M | 14.2 M | 11.8 M | 10.3 M | 9.2 M | 9.34 M | 8.13 M | 7.57 M | 6.88 M | 8.13 M | 6.82 M | 5.04 M | 3.44 M | 2.92 M | 3.63 M | 3.29 M | 13.3 M | - | 11.6 M | 11.6 M | 11.6 M | 2.2 M | 4.4 M | 1.35 M | 3.17 M | - | 5.19 M | 5.47 M | 7.67 M | - | 10.1 M | 10 M | 8.94 M | - | 9.43 M | 8.4 M | 6.63 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50 M | 1.35 M | 17.4 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.74 | - | $ 5.47 K | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.38 | - | $ 266 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.59 | - | $ 36.7 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.07 | - | $ 1.63 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.7 | - | $ 347 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.19 | - | $ 47.5 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.6 | - | $ 122 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 88.6 | - | $ 12 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.9 | - | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.31 | - | $ 717 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.14 | - | $ 1.59 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.0 | - | $ 16.9 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.63 | - | $ 2.97 B | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.94 | - | $ 374 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.89 | -2.81 % | $ 70.4 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 86.28 | - | $ 111 B | ||
|
Align Technology
ALGN
|
4 B | $ 171.87 | - | $ 12.9 B | ||
|
Myomo
MYO
|
40.9 M | $ 0.7 | - | $ 29.3 M | ||
|
AxoGen
AXGN
|
225 M | $ 32.64 | - | $ 1.5 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.77 | - | $ 466 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Penumbra
PEN
|
1.4 B | $ 329.87 | - | $ 12.8 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 203.5 | - | $ 14.3 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.53 | 0.4 % | $ 7.02 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.13 | -0.24 % | $ 874 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Smith & Nephew plc
SNN
|
4.56 B | $ 32.63 | - | $ 23.8 B | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 332.3 | - | $ 127 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 24.57 | - | $ 562 M | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.63 | 5.47 % | $ 29.6 M | ||
|
TransMedics Group
TMDX
|
605 M | $ 104.8 | - | $ 3.56 B | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 19.17 | - | $ 1.3 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M |